Recent work highlights that a progressive increase in FGF-23 and sclerostin in blood and bone is associated with a decrease in kidney function, which suggests using the correlations of bone turnover and sclerostin or FGF-23 could improve patient management in CKD patients with turnover abnormalities [59,60,61,62,63]. Here, FGF23 is linked to chronic kidney disease.